428 Pharma - Ra'anana, Israel

A group of ex-high-level Teva executives with a combined total of 60+ years of experience and more than 60 projects in diagnostic testing and 505(b)(2) drug development have been granted exclusive global rights to two of the most promising Teva assets, which were made available due to Teva's recently publicized Research & Development restructuring and divestment.